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ABSTRACT
Bunyaviruses are emerging viral pathogens that cause encephalitis, hemorrhagic
fevers, and meningitis. Rift Valley fever virus is a particularly devastating bunyavirus,
infecting both humans and livestock with significant morbidity and mortality.
By coordinating several host and viral processes Rift Valley fever virus is able
to produce infectious virions. Polyamines are small, positively-charged host-derived
molecules that play diverse roles in human cells and in infection. We previously
demonstrated that polyamines are crucial for RNA viruses; however, the mechanisms
by which polyamines function remain unknown. Here, we investigated polyamines’ role
in the replication of the Rift Valley fever virus (vaccine strain MP-12). We found that
polyamine depletion did not impact viral RNA or protein accumulation. Viral particles
demonstrated no change in morphology, size, or density, however, targeting polyamines
significantly reduced viral titers. In sum, polyamine depletion results in the accumulation
of noninfectious particles which has important implications for targeting polyamines
therapeutically, as well as enhancing vaccine strategies.

xi

CHAPTER 1: BACKGROUND
Review of Literature
Rift Valley Fever Virus: an Overview
The sudden emergence of viral pathogens is of great concern since they
devastate both human and veterinary health (1). The National Institute of Allergy and
Infectious Disease categorizes emerging infectious diseases by the organism/pathogen
which possess the highest health risk to national security and public health. Category A
pathogens are of the highest priority since they can easily be transmitted, result in high
morbidity rates, cause mass social disruption, and require immediate action from
healthcare professionals (2). Within this category are Bunyaviruses (2). Bunyaviruses
are of particular interest because this viral family is the largest family with more than
350 member viruses (3). With so many viruses in this family, the potential for outbreaks
is great and current reports have noted a recent outbreak of Rift Valley fever, caused by
Rift Valley fever virus (RVFV)(4, 5).
RVFV is currently restricted to Africa and the Middle East. The disease was first
identified and characterized in 1930 by Dauney et al. (6) in Kenya. From its
identification, it remained a serious health concern for in East Africa and subsequently,
the first major outbreak was reported in 1977 in Egypt (7). The second major outbreak
occurred in 2000 moving from East Africa to Saudi Arabia and Yemen in the Arabian
Peninsula (7, 8). Outbreaks continued in Kenya, Somalia, Tanzania in 2007,
Sudan in 2008 and 2010, and more recently in Uganda and Niger in 2016 (4, 7). RVFV
1
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appears to have excellent potential for spreading to new areas and therefore must be
further studied to persevere human and animal health.
RVFV, the causative agent of Rift Valley fever, normally causes an acute febrile
illness which can escalate and cause severe disease including encephalitis,
hemorrhagic fever in humans, as well as spontaneous abortion in domesticated animals
(7, 9). RVFV is an arthropod-borne virus (arbovirus) that infects a wide range of wild
and domestic vertebrate species, mainly ruminants such as sheep, cattle, and goats
(10, 11). The primary and secondary vectors of RVFV are the Aedes and Culex
mosquitos(12). The RVFV transmission cycle, summarized in Figure 1, is maintained
through horizontal transmission, direct contact transmission with infected tissue and
fluid, and suspected vertical transmission between mosquitos and ruminants with
humans being considered as the dead-end host (11, 13).
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Figure 1. Transmission Cycle of RVFV.
Arrows represent transmission direction. Solid green lines represent established routes of horizontal
transmission from collected data. Solid red lines represent established routes of direct contact
transmission from infected tissue and fluids. Dotted lines, both green and red, are suspected routes of
vertical transmission but current data is insufficient. Adapted and modified image from (11).

Outbreaks of RVFV often force a heavy restriction on livestock movement to
prevent spread, causing massive economic loss. In addition, a major concern for society
would be the continued spread of RVFV and the spread of other bunyaviruses. A
distantly related bunyavirus, La Crosse virus (LACV) also causes encephalitis following
infection transmitted by a mosquito bite and is primarily localized to midwestern and
mid-Atlantic states of the USA (14, 15). Further, the rapid dissemination of several other
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arboviruses like chikungunya (16) and Zika (17) viruses (ZIKV) demonstrate the
extreme epidemic potential of arboviruses, including bunyaviruses.
Rift Valley Fever Virus Structure, Life Cycle, and Production
To remain pathogenic, viruses must maintain infectivity following successful
replication of their viral genomes (Figure 2). RVFV has a tripartite negative-stranded
RNA genome which is comprised of small (S), medium (M), and large (L) segments(18).
The S segment (1.7 kB) is of ambisense orientation consisting of 2 proteins: the
nucleoprotein (N) and a nonstructural protein (NSs protein). The M segment (3.2 kB)
encodes the glycoproteins, Gn and Gc, and a 78 kD protein with an unknown function.
Lastly, the L segment (6.4 kB) encodes the RNA-dependent RNA polymerase (L
protein)(18, 19).

Figure 2. Schematic Diagram of Rift Valley Fever Virus
The panel above illustrates the RVFV virion containing the S, M, and L RNA segments in addition to the
glycoproteins incorporated in the envelope. The arrows indicate the direction of viral protein production.
The viral proteins include the polymerase (L), glycoproteins (Gc and Gn), Nonstructural M protein (NSm),
Nonstructural S protein (NSs) and nucleoprotein (N).
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All viruses must complete an entire replication cycle in host cells to produce
viable progeny. Figure 3 depicts the viral life cycle of RVFV. It first attaches to an
unknown host cell receptor mediated by interactions of viral glycoproteins and host
proteins. Through receptor-mediated endocytosis, the virus enters the cell in an early
endosome. The virion will fuse to the endosomal membranes upon acidification and
undergoes viral uncoating. The release of the viral RNA (vRNA) into the cytoplasm
begins primary transcription of the vRNA to produce complementary RNA (cRNA) for
translation and additional transcription. Viral proteins are produced and are transported
to the ER-Golgi complex where encapsidation occurs followed by egress at the plasma
membrane (20). These several factors (shown in Figure 2 and Figure 3) are essential
for RVFV and contribute to the infectivity of progeny bunyaviruses (21), inclusion of
replicative proteins (L and N proteins), and successful envelopment.
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Figure 3. Bunyavirus Replication Cycle.
The viral life cycle beings with attachment of virus to a host receptor. The virus undergoes receptor
mediated endocytosis and enters the cell. Uncoating follows upon acidification and fusion with the
endosome. Transcription of the viral RNA begins to produce complementary S, M, and L segments.
Transcription of viral RNA continues in addition to translation of viral proteins. The proteins are
transported to the ER-Golgi complex for further synthesis and encapsidation. Maturation of the virion
occurs and egresses from the plasma membrane.

It is important to note that the proportion of infectious virions versus noninfectious
particles in RNA virus infection is low, with noninfectious particles outnumbering
infectious particles by 100- to 1000-fold (22). An example of this phenomenon is for
Bunyamwera virus, a related bunyavirus (22). The factors contributing to this ratio are
multifactorial, but have important implications for infection and pathogenesis (23). The
noninfectious particles can serve as decoys from immune system neutralization,
enhancing infection by infectious particles (24, 25). In contrast, noninfectious particles
can interfere with productive infection, by binding cellular receptors or usurping cellular
and viral machinery from infectious viruses (26). Defective genomes play a role in
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pathogenesis; for example, paramyxoviruses persist in their hosts by maintaining a
balance of replication and apoptosis, which is modulated by defective viruses (27).
Additionally, arthropod-borne viruses persist in their hosts at least partially through
defective viral genomes feeding into host immune defenses such as the RNAi pathway
(28). The precise mechanisms by which viruses produce defective genomes remains to
be understood for several viral families. Importantly, the cellular contribution to this ratio
of infectious-to-noninfectious virus is unclear.
Role of Polyamines in Viral Infection
Polyamines are small, positively-charged molecules found abundantly in all cells.
Mammalian cells exclusively synthesize three biogenic polyamines(29). Within a cell,
arginine is converted to ornithine which is the first step in this synthetic pathway, shown
in Figure 4. Ornithine is converted into the polyamine putrescine via the gatekeeping
enzyme of the pathway, ornithine decarboxylase 1 (ODC1). Following synthesis of
putrescine, an enzyme, spermidine synthase (SRM), coverts putrescine to spermidine.
Spermidine is then converted to spermine with spermine synthase (SMS).
Subsequently, spermine can be converted back to spermidine via spermine oxidase
(SMOX) and putrescine via spermidine/spermine acetyltransferase (SAT1) and
polyamine oxidase (PAOX)(29). The polyamine synthesis pathway is important for many
cellular processes, such as cell cycling, nucleic acid binding, and altering membrane
fluidity (30–32).
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Figure 4. Biosynthesis Pathway of Polyamines and Drug Inhibitors
Polyamine synthesis begins with arginine being converted into ornithine. ODC1, the rate-limiting enzyme,
converts ornithine to putrescine. Putrescine is converted to spermidine via SRM. Spermidine is converted
to spermine via SMS and converted back via SMOX. Spermine and spermidine can be acetylated by
SAT1 and converted back to putrescine via PAO. DFMO is an irreversible inhibitor to ODC1 preventing
polyamine synthesis and DENSpm activates SAT1 to acetylate spermidine and spermine which will
convert back to putrescine or are exported out of the cell. Image adapted and modified from (33).

With the abundance of polyamines being utilized in cells for diverse processes, it
is not surprising that viruses use polyamines for their own replication. Viruses like
herpes simplex 1 (HSV1), vaccinia virus (VACV), and human cytomegalovirus (HCMV)
have been reported to contain polyamines within the virion and are involved in viral
packaging (34–36). Ebolavirus, Marburgvirus, and human immunodeficiency virus
(HIV-1) utilize polyamines in translation through the hypusination of eukaryotic
translation initiation factor 5A (eIF5A) (37–39). Additionally, the depletion of polyamines
reduces viral titers of many RNA viruses and was first demonstrated with an infrequent
human pathogen found in the alphavirus family, Semliki Forest virus (SFV) (29, 40). The
polyamine pathway has been considered a pharmacological target for numerous
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cancers and targeting this pathway could be a feasible way to reduce various viral
infections. An FDA approved drug, difluormethylornithine (DFMO) is a specific, nontoxic
inhibitor of ODC1 (Figure 4). By reducing cellular or organismal polyamine levels, it is
used to target diverse cancer types and is the primary treatment for trypanosomiasis
(41, 42). Despite a reliance on polyamines for cellular growth and division, polyaminedepleted mammalian cells maintain viability without significant toxicity (43, 44).
Additionally, N1,N11-diethylnorspermine (DENSpm) is another pharmacological agent
with therapeutic potential. Treatment of cells with DENSpm results in the upregulation of
SAT1 and subsequent acetylation of spermidine and spermine(29). This acetylation
results in an increase of reconverted putrescine or export of these polyamines from the
cell (29, 45, 46) (Figure 4). These pharmacological agents are promising therapeutics,
and they also provide valuable tools to study the roles of polyamines in virus infection. It
is not known whether bunyaviruses utilize polyamines and with these pharmalogical
agents, we can assess whether these drugs work against RVFV.
Aims and Hypothesis
Recent studies demonstrated that RNA viruses rely on polyamines for replication
(29). Initially, it was found that positive-stranded RNA viruses, like chikungunya and
Zika virus, required polyamines for translation of the viral polyprotein as well as viral
RNA-dependent RNA polymerase activity (47). Olsen et al. uncovered that Ebola virus
relies on polyamines for translation of viral proteins through the spermidine metabolite
hypusine (37–39). It was further shown that a range of RNA viruses rely on polyamines
for replication, both in vitro and in vivo (48). Prior work has established a role for

10
polyamines in virion packaging of nucleic acid in several DNA viruses (34–36). RNA
viruses, in contrast, were characterized to package negligible levels of polyamines (49).
Additionally, Mounce et al. highlighted the importance of the polyamine biosynthetic
pathway as a target in the development of future antivirals. Upon depletion of
polyamines through different pharmalogical agents that target the key players in
polyamine biosynthesis, viral replication was severely limited (48). Currently, little is
understood about polyamines in the viral lifecycle of bunyaviruses like RVFV. The goal
of this proposal is to determine how polyamines may be involved in virus production and
how they modulate RVFV infectivity.
In AIM 1, we examined whether polyamine depletion alters RVFV infection. I
hypothesized that RVFV, like other RNA viruses, would be affected by polyamine
depletion. Results from this aim establish the importance of polyamines for RVFV and to
identify where polyamines may play a role in the RVFV replication cycle.
In AIM 2, I assessed virion production and composition of RVFV from cells with
and without polyamines. I hypothesized that polyamines are essential for proper
production of infectious RVFV; thus, in the absence of polyamines, infectious virion
composition is compromised. The goal of this aim was to investigate RFVF genome
abundance, size, and functionality in the presence of polyamine depleting drugs.
In AIM 3, I proposed that polyamines contribute to the gross architecture of
RVFV. I hypothesized that RVFV utilizes polyamines for proper virion maturation like
VACV and HSV1. The goal of this aim was to define the direct or indirect impact on the
physical properties of RVFV in the presence of polyamine depleting drugs.
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The data generated from these aims demonstrated that RVFV uses polyamines
for its replication. Although there was no change in morphology and viral protein levels
were unchanged, we see an increase in RVFV genome-to-PFU ratio and a reduction in
viral titer.

CHAPTER 2: MATERIALS AND METHODS
Cell Culture
Cells were maintained at 37⁰C in 5% CO2, in Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies) with bovine serum and penicillin-streptomycin.
Vero cells (BEI Resources) were supplemented with 10% new-born calf serum (NBCS;
Thermo-Fischer) and Huh7 cells, kindly provided by Dr. Susan Uprichard, were
supplemented with 10% fetal bovine serum (FBS; Thermo-Fischer). THP1 cells were
donated by Dr. Makio Iwashima and maintained in RPMI (Thermo-Fischer)
supplemented with 2% FBS and beta-mercaptoethanol (BME, 50mM; Thermo-Fischer).
THP1’s were differentiated with phorbol 12-myristate 13-acetate (PMA, 100 pg/ mL;
Thermo-Fischer). RAW264.1 macrophages were provided by Dr. Katherine Knight and
maintained in 2% FBS.
Drug Treatment
Difluoromethylornithine (DFMO; TargetMol) and N1,N11-Diethylnorspermine
(DENSpm; Santa Cruz Biotechnology) were diluted to 100x solution (100mM and
10mM, respectively) in sterile water. For DFMO treatments, cells were trypsinized
(Zymo Research) and reseeded with fresh medium supplemented with 2% serum.
Following overnight attachment, cells were treated with 100 µM, 500 µM, 1 mM, or 5
mM DFMO. Cells were incubated with DFMO for 96 hours to allow for depletion
of polyamines in Huh7 cells. For DENSpm treatment, cells were treated with 100 nM, 1
12
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µM, 10 µM, 100 µM, and 1mM 16 hours prior to infection. During infection,
media was cleared and saved from the cells. The same medium containing DFMO and
DENSpm was then used to replenish the cells following infection. Cells were incubated
at the appropriate temperature for the duration of the infection.
Infection and Enumeration of Viral Titers
MP-12 (50), LACV, and KEYV were derived from the first passage of virus in
Huh7 cells. ZIKV (MR766) was derived from the first passage of virus in Vero cells.
CVB3 (Nancy strain) was derived from the first passage of virus in HeLa cells. ZIKV,
LACV, and, KEYV were obtained from Biodefense and Emerging Infections (BEI)
Research Resources. For all infections, DFMO and DENSpm were maintained
throughout infection as designated. Viral stocks were maintained at -80⁰C. For infection,
virus was diluted in serum-free DMEM for a multiplicity of infection (MOI) of 0.1 on Huh7
cells, unless otherwise indicated. Viral inoculum was overlain on cells for 10 to 30
minutes, and the cells were washed with PBS before replenishment of media.
Supernatants were collected from MP-12, LACV, KEYV, ZIKV, and CVB3 24 hpi.
Dilutions of cell supernatant were prepared in serum-free DMEM and used to inoculate
confluent monolayer of Vero cells for 10 to 15 min at 37⁰C. Cells were overlain with
0.8% agarose in DMEM containing 2% NBCS. CVB3 samples incubated for 2 days,
MP-12, ZIKV, and LACV samples incubated for 3 days and KEYV samples incubated
for 5 days at 37⁰C. Following appropriate incubation, cells were fixed with 4% formalin
and revealed with crystal violet solution (10% crystal violet; Sigma-Aldrich). Plaques
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were enumerated and used to back-calculate the number of plaque forming units (pfu)
per milliliter of collected volume.
Thin Layer Chromatography Determination of Polyamines
Polyamines were separated by thin-layer chromatography as previously
described (Madhubala, 1998). For all samples, cells were treated as described prior to
being trypsinized and centrifuged. Pellets were washed with PBS and then resuspended
in 200 uL 2% perchloric acid. Samples were then incubated overnight at 4⁰C. 200 uL of
supernatant was combined with 200 uL 5 mg/ml dansyl chloride (Sigma Aldrich) in
acetone and 100 uL saturated sodium bicarbonate. Samples were incubated in the dark
overnight at room temperature. Excess dansyl chloride was cleared by incubating the
reaction with 100 µL 150 mg/mL proline (Sigma Aldrich). Dansylated polyamines were
extracted with 50 µL toluene (Sigma Aldrich) and centifuged. 5 µL of sample was added
in small spots to the TLC plate (silica gel matrix; Sigma Aldrich) and exposed to
ascending chromatography with 1:1 cyclohexane: ethylacetate. Plate was dried and
visualized via exposure to UV.
Polyamine Luciferase Reporter Assay
To measure free polyamine levels in cells, a dual-luciferase vector containing the
wild-type -1 frameshift antizyme OAZ1 (pC5730), kindly sent to us by Dr. Tom Dever
from the National Institutes of Health, were transfected into cells with LipoD293
(SignaGen). Free polyamines modulate OAZ1 mRNA frameshifting and these
constructs can measure relative endogenous polyamine concentrations via a dualluciferase reporter as previously described (51) Huh7 cells were seeded with 2% media
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and drug treated as described above. Cells were transfected with 62.5 ng of reporter
plasmid of and after 24 hours of incubation, luminescent signal was measured using the
Dual-Luciferase Reporter Assay System (Promega) by measuring both firefly and
Renilla luciferase with the Veritas Microplate Luminometer (Turner Biosystems). Firefly
luciferase was normalized to Renilla and the wild-type values and subsequently
normalized to untreated controls.
Virus Preparation and Concentration
MP-12 was inoculation onto confluent Huh7 cells at an MOI of 0.001 and
incubated for 48-72h, until full CPE. Supernatant was clarified via centrifugation and
then concentrated using VivaSpin 20 centrifugal concentrators (GE Lifesciences). Virus
was concentrated 1000-fold by resuspending in an appropriate amount of serum free
DMEM.
RNA Purification and cDNA Synthesis
Media was cleared from cells and Trizol reagent (Zymo Research) directly
added. Lysate was then collected, and RNA was purified according to the
manufacturer’s protocol utilizing the Direct-zol RNA Miniprep Plus Kit (Zymo Research).
Purified RNA was subsequently used for cDNA synthesis using High Capacity cDNA
Reverse Transcription Kits (Thermo-Fischer), according to the manufacturer’s protocol,
with 10-100 ng of RNA and random hexamer primers.
Viral Genome Quantification
Following cDNA synthesis, qRT-PCR was performed using the QuantStudio3
(Applied Biosystems by Thermo-Fischer) and SYBR green mastermix (DotScientific).
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Samples were held at 95⁰C for 2 mins prior to 40 cycles of 95⁰C for 1s and 60⁰C for 30s.
Primer sequences are included in Table 1. Primers were verified for linearity using
eight-fold serial diluted cDNA and checked for specificity via melt curve analysis
following by agarose gel electrophoresis. All samples were used to normalize to total
RNA using the ΔCT method. Primer sequences are included in Table 1.
Table 1. Primers Utilized in This Study
Primers (qRT-PCR)
MP12 - Small
Segment
MP12 - Medium
Segment
MP12 - Large
Segment
ZIKV
CVB3
GAPDH

Forward
Reverse
5'-CAGCAGCAACTCGTGATAGA-3' 5'-CCCGGAGGATGATGATGAAA-3'
5'GGAACTAGGGAAGACTGAGAGA3'
5'CTCCACTAACCCAGAGATGATTG3'
5'CCCTCAAGTATAGCAGCAAGAG3'
5'-GGAAGCACGGGTCCAATAAA3'
5’-GATTCCACCCATGGCAAATTC3’

5'-CTGCTGAAGGGTGGAAACA-3'
5'-CTCCTGGCTTGAGGTCTTAAC-3'
5'-TGAGTTGGAGTCCGGAAATG-3'
5'CAGAGTCTAGGTGGTCTAGGTATC3'
5’-CTGGAAGATGGTGATGGGATT-3’

Genome-to-PFU Ratio Calculations
The number of viral genomes quantified as described above were divided by the
viral titer, as determined by plaque assay, to measure the genome-to-PFU ratio. Values
obtained were normalized to untreated conditions to obtain the relative genome-to-PFU
ratio.
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Western Blot
Samples were collected with Bolt LDS Buffer and Bolt Reducing Agent
(Invitrogen) and run on polyacrylamide gels. Gels were transferred using the iBlot 2 Gel
Transfer Device (Invitrogen). Membranes were probed with primary antibodies for Rift
Valley Fever nucleoprotein, N, glycoprotein N, GN, (1:500, BEI Resources) and, β-actin
(1:5000, Santa Cruz Biotechnology). Membranes were treated with SuperSignal West
Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific) and visualized on
ProteinSimple FluorChem E imager.
Silver Stain
Samples were collected with Bolt LDS Buffer and Bolt Reducing Agent
(Invitrogen) and run on polyacrylamide gels. Gels were then washed with a fixative
solution (50% methanol, 12% acetic acid, 0.05% formaldehyde) for 2 to 24 hours. After
fixing, the gels were washed with a wash solution (35% ethanol) for 20 minutes and was
repeated three times. Gels then were placed in a sensitizer solution (0.02% sodium
thiolsulfate) for 5 minutes followed by 3 brief rinses with ddH2O. Following the brief
rinsing steps, the gels sat in a staining solution (0.2% silver nitrate, 0.076%
formaldehyde) for 20 minutes. After the stain, the gels were washed with ddH2O and the
gels were revealed with developing solution (6% sodium carbonate, 0.05%
formaldehyde, and 0.0004% sodium thiol sulfate) for 1 to 5 minutes. The reaction was
then stopped with a stop solution (12% acetic acid) for 5 minutes and gels were stored
in H2O at 4⁰C.
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Indirect Immunofluorescence
Huh7 cells grown on cover slips were either treated with 500 µM DFMO or
untreated. After four days cells were infected with MP12. Cells fixed with 4% formalin for
15 minutes, washed with PBS, permeabilized and blocked with 0.2% Triton X-100 and
2% BSA in PBS (blocking solution) for 30 minutes at room temperature (RT). Cells were
sequentially incubated as follows: Primary mouse anti-Nucleoprotein antibody (1:100 in
blocking solution, overnight at 4oC), and secondary antibody, goat anti-mouse 488nm,
(1:500 in PBS, 1hr, RT). Cells were then incubated in affinity pure Fab donkey antimouse IgG fragment (1:100 in blocking solution, Jackson ImmunoResearch, 1hr RT),
followed by primary mouse anti-RNA (J2) antibody (1:100) and 633nm conjugated
phalloidin (1:500) in blocking solution (overnight at 4oC) and then secondary donkey
anti-mouse 568nm (1:500 1hr at RT). After washing with PBS, cells were mounted with
Invitrogen ProLong Diamond Antifade Mounting Media with DAPI for 30 min before
imaging. To ensure that there was no binding of the 2nd fluorescent primary antibody to
the first primary mouse antibody, control cells were processed as described above, but
without the 2nd primary antibody step. Samples were imaged with Zeiss Axio Observer
7 with Lumencor Spectra X LED light system and a Hamamatsu Flash 4 camera using
appropriate filters using Zen Blue software with a 40X objective.
Electron Microscopy
Concentrated Rift Valley Fever Virus (RVFV) samples were prepared for imaging
by transmission electron microscopy according to a published method (Ellis et al., 1988)
with minor modifications. Concentrated RVFV samples suspended in media were fixed
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in 5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) for 24 h at room
temperature. Fixed viral samples were subjected to ultracentrifugation then
resuspended in 50 µl deionized water. Next, 5 µl of sample was pipetted onto a formvarand carbon-coated 200 mesh copper grid (Electron Microscopy Sciences) held in place
by negative-action tweezers. Five minutes later, the edge of the grid was blotted with a
wedge of Whatman filter paper to remove excess sample. The sample was negatively
stained by immersing the grid in a 1% solution of phosphotungstic acid (PTA) (pH 6.8)
for 1 min. After the grid was removed from the 1% PTA solution, the edge of the grid
was blotted with a wedge of Whatman filter paper, and the sample was allowed to air
dry for 5 min. The sample was placed into a grid storage box and allowed to dry for 24 h
prior to imaging with a Philips CM120 transmission electron microscope (TSS
Microscopy, Beaverton, OR) equipped with a BioSprint 16 megapixel digital camera
(Advanced Microscopy Techniques, Woburn, MA). (52)
Particle Size Measuring
We obtained images of viral particles via transmission electron microscopy
(TEM) and negative staining. ImageJ was used to measure the diameter of the particles
by measuring the provided standard from the TEM imaging software and measuring the
particles which were then normalized to the standard.
Fractionation
Sucrose gradient ultracentrifugation was performed using an Optima L-90K
ultracentrifuge with an SW60 Ti Beckman rotor and Ultra-Clear Centrifuge tubes (11x
60mm; Beckman Coulter). Varying densities of sucrose (20%-60%) was added to the
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centrifuge tubes in 2.5% increments between 20% and 30% and 5% increments
between 30% and 60%. Tubes were weighed before adding 50 ul to 200 ul of viral
supernatant, unless otherwise indicated. Centrifuge tubes were then spun at 45,000
RPM for 18 hours at 4⁰C. Samples were then collected based on fraction amount (450
uL) and analyzed by western blot, silver stain, and RT-qPCR.
Total Polyamine Assay
Huh7 cells were plated and either treated with 500 µM DFMO or untreated. After
four days, cells were infected with MP12, VACV, and CVB3 at an MOI of 0.1 for 48
hours. Supernatant was collected. 20% sucrose was added to the centrifuge tube and
tubes were weighed before adding 1mL of viral supernatant, unless otherwise indicated.
Centrifuge tubes were then spun at 18,000 RPM for 1.5 hours at 4⁰C. Pellets were then
collected and Total Polyamine Assay Kit (BioVision Incorporated) was used and
analyzed fluorescence of the whole sample with Synergy H1 microplate reader
(BioTek).
Statistical Analysis
Prism 6 (GraphPad) was used to generate graphs and perform statistical
analysis. For all analyses, one-tailed Student’s t test was used to compare groups,
unless otherwise noted, with a = 0.05. For tests of sample proportions, p values were
derived from calculated Z scores with two tails and a = 0.05.

CHAPTER 3: RESULTS
RVFV is Sensitive to Polyamine Depletion.
Previous data focused on the role of polyamines in alphavirus and flavivirus
replication (47). It was further demonstrated that polyamines are required for a number
of distinct viral families (48). We understand little about potential roles for polyamines in
these diverse viruses, however, to initially examine polyamines in RVFV replication, we
sought to determine their sensitivity to polyamine depletion. DFMO at a concentration of
500 μM was sufficient to block alpha- and flavivirus replication(47, 48); thus, we
investigated whether these parameters would similarly reduce RVFV infection (the
vaccine strain of RVFV). We treated Huh7 cells with 500 μM DFMO for four days prior
to infection at a multiplicity of infection (MOI) of 0.01 plaque-forming units (pfu) per cell
with the vaccine strain of RVFV, MP-12. Samples were collected every eight hours and
titered on Vero-E6 cells. We observed characteristic sigmoidal growth kinetics of
untreated cells; however, DFMO-treated cells failed to produce virus (Figure 5A). In fact,
viral titers remained flat over 64 hours of infection, suggesting that MP-12 failed to
replicate without polyamines.
To measure sensitivity to DFMO and, thereby, polyamine depletion, we treated
Huh7 cells with increasing doses of DFMO, from 100 μM to 5 mM and measured virus
replication at 48 hours post infection (hpi) via plaque assay. We observed a
significant decrease in titer when cells were treated with a minimum of 500 μM DFMO
(Figure 5B). Both 1 mM and 5 mM treatments significantly reduced titers as well. We
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verified that DFMO was depleting polyamines using a quantitative polyamine-sensitive
luciferase assay (53), which demonstrated significant reductions in polyamine levels at
all tested concentrations (Figure 5C). To visually confirm that these doses of DFMO
were, in fact, depleting polyamines, we performed thin-layer chromatography (TLC) on
polyamines. We found that, compared to untreated samples, DFMO treatment as low as
100 μM reduced polyamine levels and were undetectable at 500 μM (Figure 5D).

Figure 5. Rift Valley Fever Virus MP-12 is Sensitive to DFMO Treatment.
(A) Huh7 cells were left untreated or were treated with 500 µM DFMO for four days prior to infection at a
multiplicity of infection (MOI) of 0.01 plaque-forming units of RVFV MP-12 strain per cell. Samples were
collected every 8 h for 64 h and subsequently titered via plaque assay.
Huh7 cells were treated with escalating doses of DFMO as indicated and subsequently infected with (B)
MP-12 at an MOI of 0.1 pfu per cell. Viral titers were determined at 48 h post infection.
(C) Intracellular polyamine levels were measured using a dual luciferase assay reporter of an OAZ1
transcript construct following DFMO treatment for four days. Relative luciferase activity was normalized to
untreated samples.
(D) Thin layer chromatography on cells treated as in (B) to measure biogenic polyamine levels following
DFMO treatment. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n ≥ 3) comparing untreated
cells to DFMO treatment. Error bars represent ± 1 SEM. Statistical comparison were performed between
treated and untreated conditions.

23
We next investigated whether MP-12 was sensitive to DENSpm. First, we
performed a growth curve of MP-12 using 100 μM DENSpm, an activator of SAT1 which
acetylates polyamines, leading to their neutralization and export from the cell (45, 46).
We observed significant decreases in viral titers over a course of infection (Figure 6A).
Using a range of DENSpm concentrations, we observed a decrease in MP-12 titers at
concentrations greater than 50 μM (Figure 6B), similar to our data with other viruses
(48). We confirmed via TLC and ImageJ quantitation of chromatogram that DENSpm
reduced polyamine levels (Figure 6C and D).

Figure 6. Rift Valley Fever Virus MP-12 is Sensitive to DENSpm Treatment.
(A) Huh7 cells were treated with 100 µM DENSpm for 16h prior to infection with MP-12 at an MOI of 0.01.
Samples were collected every 8 h for 32 h and titered via plaque assay.
(B) Huh7 cells were treated with escalating doses of DENSpm as indicated and infected with MP-12
at an MOI of 0.01 pfu per cell. Viral titers were determined at 48 hpi.
(C) Relative polyamine levels as measured by thin layer chromatography (D) were quantified via ImageJ
analysis and normalized to untreated controls. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n
≥ 3) comparing untreated cells to DFMO treatment. Error bars represent ± 1 SEM. Statistical comparison
were performed between treated and untreated conditions.
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RVFV Genome-to-PFU Ratio is Increased with Polyamine Depletion.
Reports have suggested that polyamines are present in the virions of diverse
viruses and promote genome packaging (34, 35). We hypothesized that polyamines
may function similarly for RVFV. To test whether polyamines are involved in RVFV
packaging, we aimed to quantify the ratio of the number of genomes per virus in
infected cell supernatant. To this end, we treated Huh7 cells with DFMO and
subsequently infected with MP-12 at MOI 0.1 for 48h. We titered the virus and
measured the number of genomes (small [S], medium [M], and large [L] segments) via
quantitative Real Time-PCR (qRT-PCR) with genome-specific primers. As in Figure 5B,
we observed reduced MP-12 titers with DFMO treatment (Figure 7A). We anticipated
that if polyamines were involved in packaging, we would observe significantly fewer viral
genomes in the infected cell supernatant. Surprisingly, we observed equivalent numbers
of genomes in the supernatant with escalating doses of DFMO (Figure 7B). We next
calculated the genome-to-PFU ratio by dividing the number of viral genomes by the
titers (values in Figure 7B divided by 7A). We found a dramatic increase in the number
of viral genomes per infectious virus in a DFMO dose-dependent manner (Figure 7C).
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Figure 7. Specific Infectivity of RVFV MP-12 is Diminished with DFMO.
Huh7 cells were treated with either 500 µM or 1 mM DFMO for four days prior to infection with MP-12
at an MOI of 0.1 pfu per cell. (A) Viral titers were determined via plaque assay and (B) viral genomes in
culture supernatant was quantified via qRT-PCR at 48 hpi. (C) The relative number of viral genomes from
(B) was divided by the titer from (A) to determine the genome-to-pfu ratio, normalized to untreated
controls. Values provided above data bars represent the fold change compared to untreated conditions.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n ≥ 3) comparing DFMO treatment to untreated
controls. Error bars represent ± 1 SEM. Statistical comparison were performed between treated and
untreated conditions.

We confirmed these phenotypes by depleting cells of polyamines with DENSpm. We
treated cells with 10 or 100 μM DENSpm for 16h prior to infection at MOI 0.1. We
collected and titered (Figure 8A) and measured genomes (Figure 8B) at 48 hpi. As with
DFMO, MP-12 titers were decreased but viral genome levels were unchanged, resulting
in high genome-to-PFU ratio (Figure 8C).
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Figure 8. Specific Infectivity of RVFV MP-12 is Diminished with DENSpm.
Huh7 cells were treated with 10 or 100 µM DENSpm for 16h prior to infection with MP-12 at an MOI of 0.1
pfu per cell. (A) Viral titers were determined via plaque assay and (B) viral genomes quantified via qRTPCR at 48 hpi. (C) The ratio of viral genomes (B) was divided by the titer from (A) to determine the
genome-to-pfu ratio, normalized to untreated controls. Values provided above data bars represent the
fold change compared to untreated conditions. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n
≥ 3) comparing DFMO treatment to untreated controls. Error bars represent ± 1 SEM. Statistical
comparison were performed between treated and untreated conditions.

We next measured cell-associated viral RNA by extracting RNA from attached,
infected cells. As with supernatant RNA, we observed no change in the number of
genomes produced (Figure 9A). However, the MP-12 genomic RNA measurements
could be free RNA or virion-associated RNA. To distinguish between the two, we
treated our infected cell supernatant with RNAse A prior to genome quantification. We
observed no change in the genome-to-PFU ratio with DFMO (Figure 9B), suggesting
that a portion of supernatant genomic RNA was protected from RNAse degradation. We
presume these RNAse-protected genomes are virion-associated; however, these data
do not exclude the possibility that viral RNA could be contained in a vesicle or other
layer to protect from degradation. This phenotype was confirmed again with DENSpm
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treatment (Figure 9C). Together, these data suggest that polyamine-depleted cells have
no defect in viral genome production or export.

Figure 9. Specific Infectivity of RNAse Treated RVFV MP-12 is Diminished with
Polyamine Depletion.
(A) Huh7 cells were treated and infected as in (Fig. 7 and Fig. 8) and the number of cell-associated viral
genomes was determined via qRT-PCR, normalizing to cellular GAPDH.
(B,C) Samples from (Fig 7B) and (Fig 8B) were treated with RNase prior to genome quantification
via qRT-PCR and divided by viral titers in (Fig 7A) and (Fig 8A) to determine the genome-to-pfu ratio.
Values provided above data bars represent the fold change compared to untreated conditions. *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001 using Student’s t test (n ≥ 3) comparing DFMO treatment to untreated controls.
Error bars represent ± 1 SEM. Statistical comparison were performed between treated and untreated
conditions.

RVFV Viral Protein Levels are Unchanged in Infected Cell Supernatant.
We observe that viral titers are reduced greater than 100-fold with DFMO
treatment (Figure 5A and B). However, genome levels are unchanged relative to the
control (Figure 7B). We hypothesized that this discrepancy could be due to aberrant
virion protein content. To test this hypothesis, we measured the levels of N and GN in
both cells and infected cell supernatant. We observed no difference between the levels
of viral proteins in the supernatant (Figure 10A), though there was a slight decrease in
viral protein content when DFMO-treated intact cells were collected (Figure 10B).
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Figure 10. RVFV MP-12 Viral Protein Levels are Unchanged in Non-Cell
Associated Virus Via Western Blot Analysis
Huh7 cells were treated with escalating doses of DFMO or left untreated for four days and subsequently
infected at MOI of 0.1 pfu per cell or left uninfected. At 48 hpi, (A) supernatant and (B) cells were
collected for western blot analysis for viral proteins GN and N, as well as cellular GAPDH.

Because we observed significant changes in N protein levels in cell-associated protein
but not in supernatant (Figure 10A and B), we investigated whether the N protein
distribution changed with DFMO treatment. To this end, we imaged the N protein as well
as double-stranded RNA (dsRNA, J2) in infected cells, either left untreated or treated
with 500 µM DFMO. We noted that the N protein localized to perinuclear speckles that
colocalized with dsRNA in both conditions (Figure 11). No significant detectable
difference was noted between treatment conditions, though signal for the N protein was
slightly reduced in DFMO treatment conditions, fitting with our observed western blot

29
results.

Figure 11. RVFV MP-12 Viral Protein Levels are Unchanged in Non-Cell
Associated Virus Via Indirect Immunofluorescence
Huh7 cells were left untreated or treated with DFMO and infected with MP-12 for 48h prior to indirect
immunofluorescence staining for nucleoprotein (N, green), double-stranded RNA (dsRNA, red), actin
(purple), and nucleic acid (blue).

As an additional control, we measured global viral and cellular protein levels in
infected cells and supernatants via silver stain gel to determine if a DFMO-modulated
non-viral protein may contribute to infectivity. Again, we observed no gross differences
in protein profiles on our silver stain gels, either in cells or in the supernatant (Figure
12A and B). These data suggest that DFMO does not alter viral protein levels in the
infected cells supernatants.
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Figure 12. RVFV MP-12 Viral Protein Levels are Unchanged in Non-Cell
Associated Virus Via Silver Stain Analysis
Samples from (Fig 10A) and (Fig 10B) were run on an acrylamide gel and analyzed for total protein
content by silver stain for supernatant (A) and cell-associated (B) proteins.

Viral Particles from Polyamine-Depleted Cells Show No Significant Physical
Differences.
We next sought to determine if polyamine depletion had any physical effect on
the virions produced from infected cells. First, we generated viruses from untreated and
DFMO-treated cells, concentrated and purified virions, and examined the particles by
electron microscopy. We observed virions of size and shape previously described
(Figure 13A) (52), with an average diameter of 90-110 nm. Intriguingly, we observed a
similar number and size from virions derived from DFMO-treated cells (Figure 13B),

31
despite a lack of infectivity. These data suggest that fully formed viral particles are being
produced but are not infectious.

Figure 13. Physical Appearance of Secreted RVFV MP-12 Virions are Unchanged
with Polyamine Depletion
(A) Huh7 cells were treated with 500 µM DFMO or left untreated and subsequently infected with MP-12 at
MOI 0.1 pfu per cell for 48 h. Secreted viruses were collected, concentrated, and purified via
ultracentrifugation prior to electron microscopy. Representative images are shown for each treatment
condition.
(B) Diameter of viral particles derived from untreated or DFMO treated cells as in (A) were measured with
ImageJ.

To determine whether polyamine depletion altered the buoyant properties of the
MP-12 virions, we employed differential sucrose gradient ultracentrifugation. Using a
20-45% discontinuous gradient, we considered total protein content by silver staining
the same fractions and observed viral proteins to a similar extent in both untreated and
DFMO-treated conditions (Figure 14A), with peaks for these proteins in fractions from
22.5-30% sucrose. We observed MP-12 N protein in gradients ranging from 22.5-30%
sucrose when analyzed by western blot, as previously described (50), for both virions
from untreated and DFMO-treated cells. (Figure 14B). Viral genomes measured via
qRT-PCR were also not statistically significantly different with polyamine depletion
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(Figure 14C). We observed a peak in viral titers in these same fractions, though titers in
DFMO treatment conditions were 10- to 100-fold lower (Figure 14D). In total, these
results suggest that DFMO-mediated polyamine depletion does not alter the buoyant
properties nor virion physical size, despite significant reductions in infectivity.

Figure 14. Physical Properties of Secreted RVFV MP-12 Virions are Unchanged
with Polyamine Depletion
Huh7 cells were treated with 500 µM DFMO or left untreated and subsequently infected with MP-12 at
MOI 0.1 pfu per cell for 48 h. Secreted viruses were collected, concentrated, and purified via
ultracentrifugation. MP-12 particles were then subjected to discontinuous sucrose gradient
ultracentrifugation, from 20% to 45% sucrose. Fractions were collected and analyzed by (A) silver stain,
(B) western blot for viral N protein, (C) plaque assay to determine viral titers and (D) qRT-PCR to detect
viral genomes. Error bars represent ± 1 SEM from n≥3.

Polyamines are Associated with RVFV MP-12 Virions
Polyamines are implicated in viral packaging for several different viruses (34–36).
The positive charges of polyamines complement the negative charges of DNA/RNA
backbone if the genome is to be packaged tightly, as it is in a compact virion. Certain
DNA viruses contain enough polyamines within the virion to sufficiently neutralize 40%
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of the negative charge of DNA (34, 35). It had been shown that RNA viruses
encapsidate polyamines to a lesser extent than DNA viruses (29). Poliovirus, human
rhinovirus 14, and encephalomyocarditis virus (EMCV) are viruses with reduced
amounts of polyamines incorporated into mature virions (54, 55). The content of
polyamines found was sufficient to neutralize 27% of the negative charge of RNA in
rhinovirus 14, 11% in EMCV, and 1.6% in poliovirus (54, 55). Alternatively, myxoviruses,
an RNA virus family including Newcastle disease virus (NDV) and influenza viruses,
have been reported to encapsidate polyamines to neutralize around 30% of viral RNA
(56). The variance in neutralization percent suggests that polyamines may contribute to
viral packaging based on viral genome size and segment composition, as well as other
poorly-defined factors. Poliovirus is a single stranded RNA virus while influenza is an 8
segmented RNA virus. RVFV having a tri-segmented genome may utilize polyamines
for efficient packaging. To test this, we generated RVFV, Coxsackie B3 (CVB3, Nancy
Strain), a single stranded RNA virus closely related to poliovirus(57), VACV, and ZIKV
from untreated and DFMO-treated cells, subsequently concentrating and purifying the
virions through ultracentrifugation. Pellets were collected, lysed and labeled for
polyamines using a total polyamine assay kit which measures polyamine concentrations
with fluorescence. In relation to the positive control (VACV) and negative control
(CVB3), we observed that polyamines are associated with purified RVFV virions. In
DFMO treated conditions, we see a reduction in polyamine fluorescence for all viruses
including RVFV. We see no significant difference between untreated and DFMO treated
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ZIKV, indicating that flaviviruses may not utilize polyamines in viral packaging; although
data supports ZIKV uses polyamine in transcription and translation (48).

Figure 15. Polyamines are Associated with RVFV MP-12 Virions
Huh7 cells were treated with 500 µM DFMO or left untreated and subsequently infected with MP-12,
CVB3, VACV, ZIKV and mock at MOI 0.1 pfu per cell for 48 h. Secreted viruses were collected,
concentrated, and purified via ultracentrifugation. Pellets were collected, lysed, and labeled. Polyamine
levels were measured using a total polyamine luciferase assay.
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CHAPTER 4: DISCUSSION
Polyamines Play a Crucial Role in RVFV Infection
Our goal was to determine how polyamines may be involved in virus production and
how they modulate RVFV infectivity. Because polyamines are ubiquitously found in all
cells at high concentrations (58), it is likely that viruses like RVFV may have evolved a
dependence on polyamines. While a role for polyamines in enzymatic activity of viral
enzymes was previously uncovered (47), it was not determined whether polyamines
were required for infectivity. Our data suggests that polyamines are crucial for the
replication of RVFV and that polyamines promote infectivity of progeny virions through
to-be-determined mechanism(s). Additionally, we reported that polyamines are crucial
for other bunyaviruses including La Crosse virus (LACV) and Keystone virus (KEYV)
(59). This study is the first to find that polyamines are required for infectivity of
bunyaviruses. Both alphaviruses and flaviviruses were sensitive to polyamine depletion
at the level of genome translation and RNA-dependent RNA polymerase activity (29);
however, these prior studies had not investigated whether non-infectious particles were
still produced from polyamine-depleted cells and whether polyamines potentially
facilitate the encapsidation of viral genomes. Here, we have generated a working model
whereby polyamines facilitate productive RVFV infection, and in the absence of
polyamines, an altered ratio of genomes per infectious virus occurs causin noninfectious
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particles to accumulate therefore reducing RVFV infection (Figure 16).

Figure 16. Proposed Model of RVFV MP-12 Infection With and Without
Polyamines.
Cells containing polyamines support robust virus replication. In contrast, infection of polyamine depleted
cells results in the accumulation of noninfectious viral particles that have an altered ratio of genomes per
infectious virus and no change in viral protein levels. As a result, polyamine depletion limits RVFV
replication.

Based on these data and others’ previous data, polyamines play pleiotropic roles
during viral infection (29). Due to their nature as small, abundant, positively-charged
molecules, it is not surprising that they affect virus infection at distinct stages. Here, we
find that for RVFV, polyamines are important for infectivity. With polyamine depletion,
infected cells produce and export viral proteins and genomes, but the produced virions
are non-infectious. Recent reports (59) demonstrated this phenotype did not hold true
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for the non-enveloped CVB3, a positive-sense RNA virus. Enteroviruses like CVB3 are
known to recombine to rapidly evolve (60), and this tendency to recombine may impede
changes in the ratio of infectious to non-infectious virus. This defining feature of these
distinct phenotypes deserve further investigation.
Polyamines Potentially Involved with RVFV Packaging
Genome packaging is an essential part of the viral life cycle. Previous work has
established that several DNA viruses encapsidate significant concentrations of
polyamines within the virion (34, 35), while several RNA viruses were found to contain
insignificant amounts of polyamines (54, 55). In the case of herpesviruses, the viral
genomes associate with histones in the nucleus (61–63) but are further neutralized by
polyamines in the capsid. Vaccinia virus also utilizes polyamines to neutralize its
genome to fold and package the viral DNA within the capsid (35). It is unclear whether
this phenotype is a function of genome size and the need to neutralize a large amount
of negatively-charged nucleic acid, versus a relatively smaller single-stranded RNA
virus genome. Additionally, RNA viruses have evolved distinct packaging mechanisms
that are not dependent on polyamines. The presence of polyamines in bunyavirus
virions (or flavivirus or alphavirus virions) remains unexplored. Our data begins to
address this idea that RVFV may utilize polyamines like VACV or HSV to neutralize its
genome for establishing a persisting infection. It is not yet understood whether virionbound polyamines affect infectivity or whether the virion stabilized by the polyamines
and needs to be further characterized.
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Polyamines Producing Defective Viral Particles
It is understood that most viruses do not possess proofreading mechanisms and
are prone to high mutation rates(64). These mutations could therefore produce
defective viral particles. These defective viral particles have received an increase in
attention and appreciation for their novel roles in viral infection. Due to their inability to
replicate independently, defective viral particles seize infectious viral (and cellular)
machinery, reducing the capacity of the infectious virus to replicate (65). Several
mechanisms have been described whereby RNA virus genomes become defective, via
error-prone polymerases, unique RNA structures, or mistakes during viral genome
replication (26). While attention has focused on how defective genomes attenuate the
infectivity of viral particles, how cellular factors contribute to defective virus production is
less clear. Our results suggest that polyamine depletion results in noninfectious virus
generation but with fully intact virions. This could establish a novel role for polyamines
where defective particles can establish an innate immune response. Mounce et al.
previously uncovered a novel role for polyamines in the innate immune response via the
polyamine-acetylating enzyme SAT1 (47). Upon interferon stimulation, SAT1 is induced
and reduces polyamine pools within cells. Whether interferon-mediated polyamine
depletion plays a role in generating defective virions from infection is an important
hypothesis for future testing. In sum, our data suggests that the polyamine pathway is
central to virus replication and reducing polyamine pools may effectively limit infection.
Our results also suggest novel strategies to attenuate viruses: polyamine-depleted cells
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produce fully assembled viruses that are non-infectious. Such an attenuation strategy
may serve well to stimulate immune responses, which may function to enhance vaccine
efficacy. While significant work remains, understanding how polyamines contribute to
virus infectivity can provide insight into basic mechanisms of virus infectivity and
highlight novel therapeutic routes.
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